Attached files
| file | filename |
|---|---|
| EX-99.2 - CHINA MEDICINE CORP | v174816_ex99-2.htm |
| EX-99.1 - CHINA MEDICINE CORP | v174816_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
AMENDMENT
NO. 1
TO
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): December 4, 2009
(Exact
name of registrant as specified in Charter)
|
Nevada
|
000-51379
|
51-0539830
|
|
(State
of Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
Guangri
Tower, Suite 702
No. 8
Siyou South 1st Street
Yuexiu
District
Guangzhou,
China 510600
(Address
of registrant’s principal executive office)
(8620)
8739-1718 and (8620) 8737-8212
(Registrant’s
telephone number, including area code)
Check the
appropriate box below in the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.
14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
AMENDMENT
NO. 1 ON FORM 8-K/A
China
Medicine Corporation
February
19, 2010
On
December 14, 2009, China Medicine Corporation
(the “Company”)
filed a Current Report on Form 8-K dated December 4, 2009 with the Securities
and Exchange Commission, with respect to its acquisition of Guangzhou LifeTech
Pharmaceuticals Co., Ltd (the “Current Report”). This Amendment No. 1
on Form 8-K/A amends the Current Report,
in order to provide the financial information required by Items 9.01(a) and
9.01(b) of Form 8-K, which the Company indicated would be provided no later than
71 days after the Current Report was required
to be filed.
|
Item
9.01
|
Financial
Statements and Exhibits
|
THIS
AMENDMENT NO. 1 ON FORM 8-K/A AMENDS ITEM 9.01 OF THE CURRENT REPORT AS
FOLLOWS:
(a) Financial Statements of
Businesses Acquired.
In
accordance with Item 9.01(a) of Form 8-K, the financial statements required
pursuant to Regulation S-X are filed as Exhibit 99.1 to this Form 8-K/A and are
incorporated in their entirety herein by reference.
(b) Pro Forma Financial
Information.
In
accordance with Item 9.01(b) of Form 8-K, the pro forma financial information
required pursuant to Regulation S-X is
filed as Exhibit 99.2 to this Form 8-K/A and is
incorporated in its
entirety herein by reference.
(d) Exhibits.
The
exhibits required by this item are listed on the Exhibit Index to this
report.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
CHINA
MEDICINE CORPORATION
|
By:
|
/s/
Senshan Yang
|
|
|
Name:
|
Senshan
Yang
|
|
|
Title:
|
Chief
Executive Officer
|
Date: February
19, 2010
Exhibit
Index
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Guangzhou
LifeTech Pharmaceuticals Co., Ltd and Guangzhou LifeTech Medicine
Technologies Co., Ltd Combined Financial Statements as of September
30, 2009 and December 31, 2008 and for the year ended December 31,
2008 and for the nine months ended September 30, 2009 and
2008.
|
|
|
99.2
|
Unaudited Pro Forma Condensed
Combined Financial Information as of September 30, 2009, for the
nine months ended September 30, 2009, and for the year ended December 31,
2008.
|